Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Trial status:Recruitment Complete
Trial ID:
BNT327-03
NCT ID:
EudraCT ID:
N/A
EU Trial (CTIS) Number:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruitment Complete
Trial Details
This is a Phase III, multisite, randomized, double-blinded study to investigate BNT327 combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
Medical Condition
Trial Drug
See more
Phase
Phase 3
Type
Interventional
Estimated Enrolment
439
Estimated Trial Date
Feb 2025 - Apr 2028
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Clermont Oncology Center
Clermont, Florida, United States, 34711
Status
Location
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana, United States, 46804
Status
Location
McFarland Clinic
Ames, Iowa, United States, 50010
Status
Location
Helen G. Nassif Community Cancer Center
Cedar Rapids, Iowa, United States, 52403
Status
Location
Baptist Cancer Center
Southaven, Mississippi, United States, 38671
Status
Location
Nebraska Hematology-Oncology (NHO)
Lincoln, Nebraska, United States, 68506
Status
Go to page